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Abstract We have investigated the effect on the substrate
requirements for guinea pig liver (tissue) transglutaminase of a
set of 11 synthetic glutamine substitution analogues making up
the full sequence of the naturally occurring tissue transgluta-
minase substrate substance P. While a number of peptide
sequences derived from proteins that are well-recognized as
tissue transglutaminase substrates have been studied, the enzyme
activity using substitution analogues of full-length natural
substrates has not been investigated as thoroughly. Thus, our
set of substance P analogues only differs from one to other by
one amino acid mutation while the length (of the peptide) is
maintained as in the natural parent peptide. Our results indicate
that a glutamine residue is not recognized as substrate by the
enzyme whether it is placed at the N- or C-terminal or between
two positively charged residues or between two proline residues.
To further address the effect on enzyme activity of charged
amino acids in the vicinity of the reactive glutamine residue, a
new set of synthetic charge replacement analogues of substance P
has been also studied. Together, the results have identified new
minimal requirements for modification of a particular glutamine
residue in a polypeptide chain. It would be of interest to set up a
full set of such requirements in order to highlight potential
glutamine residues as enzyme targets in the growing list of
proteins that are being described as transglutaminase substrates.
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1. Introduction
Tissue transglutaminase (tTG, type II TG) catalyzes a
Ca2-dependent acyl transfer reaction in which new Q-amide
bonds are formed between Q-carboxamide groups of peptide-
bound glutamine residues and a variety of primary amines [1].
Although the most obvious function of tTG is to stabilize
biological structures, there is increasing evidence that this en-
zyme is involved in many additional, more subtle processes,
like apoptotic cell death, regeneration events, receptor-medi-
ated endocytosis, cell signal transduction [2] and in the path-
ology of neurodegenerative diseases [3]. In the reaction cata-
lyzed by tTG, a glutamine residue serves as acyl donor and
the O-amino group of lysine residues as well as some poly-
amines are the physiological acyl acceptors, although non-
physiological amines can also be used by the enzyme. Thus,
when incorporated into peptides and proteins, £uorescent
amines such as monodansylcadaverine (MDC) have proved
to be useful tools for structural analysis [4^7] and peptide-
membrane interaction studies [8,9].
The number of protein glutaminyl substrates for tTG is
highly restricted, whereas the tolerance to structural di¡eren-
ces in acyl acceptors is considerable. Although reactive gluta-
mine residues are preferentially located in a £exible extension
of the molecule, very often, at both the N- and C-terminal
segment [2,10], so far, it has not been possible to derive a
consensus sequence around the speci¢c glutamine residues
from the numerous TG substrates characterized. The impact
of the primary structure surrounding a potential reactive glu-
tamine on TG-catalyzed reactions has been investigated in
early studies using peptide sequences derived from proteins
that are well-recognized as TG substrates [11^13]. Based on
these studies and some more recent contributions, Coussons et
al. [14] have proposed a set of minimal requirements for the
modi¢cation of a particular glutamine residue in a polypep-
tide chain. This glutamine must satisfy an accessibility crite-
rion (being located on solvent-exposed or £exible areas of the
protein) and in the amino acid sequence around the gluta-
mine, there must be an absence of discouraging features.
However, despite these extensive e¡orts, few studies have
dealt with the role of individual amino acid residues on en-
zyme activity using substitution analogues of full-length nat-
ural substrates.
We have previously shown that both adjacent glutamines of
the naturally occurring peptide substance P (RPKPQQ-
FFGLM-NH2) are substrates for tTG in a consecutive reac-
tion [15]. Thus, in order to determine if the proposed require-
ments are of general applicability, we decided to test as TG
substrate a set of substitution analogues of substance P. The
analogues were designed with the following criteria, (i) we
replaced Gln-6 of substance P by Asn in order to have only
Gln-5 as reactive glutamine to simplify substrate recognition
by the enzyme, we will refer to this peptide as the parent
peptide or S2 (Table 1), (ii) the glutamine residue was then
walked all along the parent peptide sequence, thus generating
a set of 10 glutamine substitution analogues of substance P
(analogues S4^S13, Table 1), (iii) the two positively charged
residues of the parent peptide, namely Arg-1 and Lys-3, were
systematically replaced by glycine or serine or omitted, thus
generating a set of seven new substance P analogues (ana-
logues S14^S20, Table 1). The full set of peptides would ad-
dress how the relative position of the reactive glutamine in-
£uences the extent of modi¢cation in an invariant peptide
sequence as well as the role of the positively charged residues
at the N-terminal vicinity of the potential reactive residue.
The overall analysis of the behavior of the full set of sub-
stance P analogues as substrates of tTG has revealed new
substrate glutamine requirements for tTG-mediated protein
modi¢cation.
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2. Materials and methods
2.1. Materials
MDC (N-(5-aminopentyl)-5-dimethylamino-1-naphtalene sulfon-
amide) was obtained from Serva (Heidelberg, Germany). Guinea pig
liver tTG (R-glutaminyl-peptide:amine-Q-glutamyltransferase, EC
2.3.2.13) was from Sigma (St. Louis, MO, USA). Salts, bu¡ers and
reagents were of the highest purity available.
2.2. Peptide synthesis
The peptides were synthesized by simultaneous multiple peptide
synthesis [16] according to standard solid phase techniques by using
9-£uorenylmethoxycarbonyl chemistry [17]. The peptides were puri¢ed
by preparative reverse phase HPLC. Analytical reverse phase HPLC
and laser desorption time of £ight mass spectroscopy were used to
determine the purity and identity of the peptides.
2.3. TG-mediated chemical modi¢cation of peptides
The tTG-mediated chemical modi¢cation of the peptides was car-
ried out using 0.4 mM peptide, 0.6 U/ml tTG, 20 mM dithiothreitol,
40 mM calcium chloride and 5 mM MDC in 100 mM Tris-HCl (pH
8.0) bu¡er. Reaction mixtures were incubated at 37‡C and stopped at
di¡erent reaction times by addition of a volume of 5% tri£uoroacetic
acid (TFA) containing water:acetonitrile (7:3, v/v). The extent of
peptide modi¢cation was quantitatively assessed by HPLC as previ-
ously described [15].
3. Results
Fig. 1 shows the time course of the tTG-mediated modi¢-
cation with MDC of representative SP analogues (sequences
for each peptide are given in Table 1). The parent peptide (S2)
apparently behaves as the native substance P sequence and it
is a good substrate for tTG. Thus, after 2 h of reaction, 94%
of the peptide has incorporated the probe on its Gln-5. On the
contrary, analogue S13 could be described as a poor gluta-
minyl substrate and no amine incorporation was detected for
analogue S6 even after a long incubation time (24 h). Ana-
logues S7, S9 and S11 are good substrates of tTG and the
percentage of modi¢ed peptide gradually increased with time,
except for analogue S7 where the degree of modi¢ed peptide
decreased for long incubation times. Furthermore, for this
analogue, we observed the appearance of high molecular
weight aggregates paralleled with the decrease in MDC incor-
poration indicative of peptide cross-linking. In this respect, it
should be mentioned that all ¢ve reactive analogues in Fig. 1
have a lysine residue in its sequence that can participate as an
intrinsic acyl acceptor in competition with the external MDC
amine. This lysine residue is preceded by proline that would
be considered as an unfavorable residue for intrinsic cross-
linking, based in the recently described requirements about
acyl acceptor lysines in proteins [18]. In this sense, no cross-
linking was detected for those analogues (S2, S9, S11 and S13)
that have lysine £anked by prolines (-PKP-). In contrast, the
analogue S7 that has a glutamine adjacent to lysine (-PKQ-)
was able to participate in cross-linking reactions. It seems that
in this case, the adverse e¡ect of a proline residue preceding a
lysine could be counteracted by a strong positive e¡ect due to
the adjacent glutamine residue. In fact, cross-linked lysine
residues with an adjacent glutamine at the C-terminal side
are frequently found in a variety of proteins in corni¢ed cell
envelopes [19,20].
Depending on the relative position of the glutamine residue,
the di¡erent synthetic substance P analogues showed pro-
nounced di¡erences as tTG substrates. Table 1 summarizes
the percentage of MDC-labelled peptide obtained from the
di¡erent analogues after 2 h of tTG incubation. At this reac-
tion time, the level of peptide cross-linking was negligible for
all 20 peptide analogues. A close examination of the results
presented in Table 1 pointed to factors that could be related
with enzyme speci¢city at the amino acid level for a glutamine
residue located in a de¢ned peptide sequence. As expected, the
analogue S3 that has the two potential reactive glutamines
substituted by asparagines was not a substrate for the enzyme.
In those analogues where glutamine was placed at the ¢rst,
second or third position from the N-terminal end, we could
not detect probe incorporation even after a long (24 h) incu-
bation time (analogues S4, S5 and S6). Conversely, those ana-
logues in which either Pro-4, Asn-6, Phe-7, Phe-8, Gly-9 or
Leu-10 was replaced by a Gln (analogues S7^S12) were found
to act as substrates in a di¡erent extent. Those analogues
Fig. 1. Time course of tTG-mediated modi¢cation of synthetic ana-
logues of substance P with MDC. (a) S2, (W) S6, (O) S7, (F) S9,
(E) S11, (R) S13. Peptide codes are listed in Table 1.
Table 1
tTG-catalyzed incorporation of MDC into synthetic analogues of
substance Pa
Code Peptide sequence mol of MDC incorporated/
mol of peptide
S1 RPKPQQFFGLM-NH2 1.00
S2 RPKPQNFFGLM-NH2 0.94
S3 RPKPNNFFGLM-NH2 0.00
S4 QPKPNNFFGLM-NH2 0.00
S5 RQKPNNFFGLM-NH2 0.00
S6 RPQPNNFFGLM-NH2 0.00
S7 RPKQNNFFGLM-NH2 0.49
S8 RPKPNQFFGLM-NH2 0.73
S9 RPKPNNQFGLM-NH2 0.84
S10 RPKPNNFQGLM-NH2 0.81
S11 RPKPNNFFQLM-NH2 0.58
S12 RPKPNNFFGQM-NH2 0.82
S13 RPKPNNFFGLQ-NH2 0.06
S14 GPKPQNFFGLM-NH2 0.90
S15 SPKPQNFFGLM-NH2 0.70
S16 PKPQNFFGLM-NH2 0.90
S17 RPGPQNFFGLM-NH2 0.85
S18 RPSPQNFFGLM-NH2 0.88
S19 RPPQNFFGLM-NH2 0.80
S20 SPSPQNFFGLM-NH2 0.80
aWe have followed the proposal of Coussons et al. [14] to number
the amino acid residues that could in£uence the reactivity of a de-
¢ned glutamine residue in the peptide sequence. As an example in
analogue RPKPNQFFGLM-NH2, glutamine is designated as posi-
tion 0, thus asparagine will be at 31, proline at 32, lysine at 33,
etc. and phenylalanine at +1, phenylalanine at +2, glycine at +3,
etc.
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designed to study the in£uence of the presence of positive
charges in the surrounding of the potential reactive residue
(i.e. analogues S14^S20) could be described as good substrates
for the enzyme showing minor di¡erences in reactivity (Table
1).
4. Discussion
We have stressed in the introduction the apparent absence
of a consensus recognition sequence for those peptides and
proteins that can act as substrate of tTG. Thus, studies ad-
dressing the sequence requirements that would de¢ne a gluta-
mine residue as tTG substrate could be of interest in order to
identify the reactive glutamine in the growing list of proteins
that are currently being described as TG substrates. In the
present paper, we have undertaken one of such studies by
means of the design and assay, as tTG substrates, of a set
of di¡erent analogues of substance P, a naturally occurring
substrate of tTG. Variations in the tTG activity on the di¡er-
ent analogues of substance P have provided new information
on the speci¢c role of a series of features that could in£uence
the recognition of a de¢ned glutamine residue by the enzyme.
These features can be grouped, based on the following crite-
ria: (i) the potential reactive glutamine residue is at the N- or
C-terminus, (ii) the presence of proline residues surrounding
the target glutamine residue, (iii) the presence of positive
charges around the target glutamine residue and (iv) how
the replacement or omission of a positive charge at the 34
or 32 position from the target glutamine residue might a¡ect
its quality as tTG substrate. The discussion below is struc-
tured following these criteria.
The two peptide analogues where the potential reactive glu-
tamine residue is located as the N-terminal residue (S4) or as
the C-terminal residue (S13) can be described as non-tTG
substrates although, as discussed later, in S4, the presence
of a proline residue at +1 could have some in£uence.
When the glutaminyl residue is located in the second or
third position away from the N-terminus, it can be recognized
by the enzyme (reviewed in [10]) even when a proline residue
precedes the glutamine residue. As reported examples that
also follow that feature, we could mention L-casein [21], ana-
logues S14^S20 in the present work, gliadin peptides [22] or
osteonectin where Gln-3 in the sequence APQQEAL- was
identi¢ed as a major substrate in the TG-catalyzed cross-link-
ing of di¡erentiating cartilage [23]. In contrast, glutamine res-
idues having a proline residue in the +1 position [20,24,25] are
rarely major targets in the TG-catalyzed cross-linking of poly-
peptide chains. As a representative example, the sodium po-
tassium ATPase inhibitor, a protein with a single glutamine
residue in its sequence followed by a proline residue (-Q5P-),
was not cross-linked by TG [26] although the protein has four
potential acyl acceptor lysines exhibiting favorable require-
ments to be used by the enzyme [18]. On the other hand,
from the proteins that have been reported to have polypeptide
sequences with proline £anking the glutamine residue, none of
such proteins were a substrate for the enzyme [20,25]. Thus,
the lack of enzyme recognition of glutamine-3 in our synthetic
analogue S6 (Table 1) can be ascribed to the presence of the
prolines around the glutamine residue that do not allow a
correct orientation of the glutaminyl substrate.
Analogue S5, that was not recognized as a substrate by the
enzyme, bears in its sequence also a proline residue at +2 that
could be considered, initially, as a potential discouraging fac-
tor. However, it has been described that a number of gluta-
mine residues in sequences -QXP- are e⁄cient substrates of
TG in both peptides [27] and proteins [6,10,21,26]. So, there
should be other factors that could explain why this peptide is
not a substrate for tTG. In fact, analogue S5 has positively
charged residues around the glutaminyl residue (arginine at
31 and lysine at +1) previously described as a discouraging
feature, particularly that at the C-terminal side of the gluta-
mine side chain [14]. In contrast, it should be mentioned that
glutaminyl residues with a positively charged side chain in the
31 position [6,25,28] or +1 position [10,20,21,29^31] serve as
substrate for TG. Thus, in order to reconcile our results with
the above mentioned references, we should consider that S5 is
not a tTG substrate because the glutamine is sandwiched be-
tween two positively charged residues. To the best of our
knowledge, only one example has been reported where a glu-
tamine £anked by basic residues (-KQK-) acts as substrate for
tTG. This is found in cross-linked peptides derived from cell
envelopes [20], although the amine donor lysine involved in
the cross-linking is generally placed in a sequence with a high
content of negatively charged residues (Asp, Glu) that can act
as charge neutralizing residues.
Replacement by glycine (or serine) of either the arginine or
the lysine or both residues at positions 32 and 34 has a
minor in£uence on peptide modi¢cation (analogue series
S14^S20, Table 1). Furthermore, small changes in MDC in-
corporation were observed after elimination of the basic res-
idue in each 34 (analogue S16) or 32 (analogue S19) posi-
tion. Thus, the positively charged residues at the N-terminal
side of the glutamine in substance P are not of importance for
determining the speci¢city. These results are in agreement
with those obtained earlier by Gorman and Folk [13] who
reported that positively charged residues to the C-terminal
side of a reactive glutamine in a synthetic model decapeptide
have a low impact on the activity of TG enzymes. In partic-
ular, it was found that the substitution of a lysine residue in
the +2 position by di¡erent amino acid residues as alanine,
glycine or leucine did not modify the speci¢city of the human
plasma factor XIII nor of the guinea pig liver enzyme.
Basically all the glutamine residues acted as amine accept-
ors in the reaction with MDC, as the target residue was
‘walked’ from the fourth N-terminal position towards the C-
terminal one (analogues S7^S12), except for the analogue S13
where the reactivity strongly declined. Analogues S9, S10 and
S12 improved markedly its quality as substrates relative to S8
and S11. It is tempting to speculate that glycines adjacent of
the target glutamine could favor the substrate accessibility. In
this sense, it has been described a number of tTG reactive
glutamines in di¡erent proteins and synthetic peptides that
have glycine either at the 31, +1 or +2 position (for discus-
sion see [6,7,10,12,13,24,26]. On the other hand, peptides S7,
S8 and S9 and the series S14^S20 provide an example about
the role of asparagine around glutamines in determining the
speci¢city. Thus, all peptides with a single Asn in either the
31 (S9) or +1 (S14^S20) position are good substrates of TG.
Analogue S7 (two asparagines to the C-terminal side of the
glutamine) was not as satisfactory as analogue S9 (two as-
paragines to the N-terminal side), which could re£ect some
in£uence of these residues adjacent to the target glutamine
[32]. As a whole, the set of substance P analogues that have
been used in the present study provides an opportunity to
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assess the role of the protein substrate’s primary structure on
the speci¢city of tTG while the native secondary structure is
appropriately retained. This approach is useful in order to
minimize the e¡ect of some other parameters on the enzyme
activity, like the overall peptide conformation, that could oc-
cur when a peptide sequence is analyzed outside its natural
protein environment.
Comparison of the results obtained in the present work
with those from Coussons et al. [14] revealed that new mini-
mal requirements for modi¢cation of a particular glutamine
residue in a polypeptide chain could be proposed in addition
to those previously reported: (i) a N- or C-terminal glutamine
residue should be considered as adverse for modi¢cation by
tTG, (ii) protein (peptide) sequences having the glutamine
residue placed both between two positively charged residues
or between two proline residues should be considered as dis-
couraging features for correct interaction with the enzyme. In
contrast, the presence of positively charged amino acids at
two or four residues away from the glutamine towards the
N-terminal side seems not to a¡ect the speci¢city of tTG.
Finally, although the basis for glutamine speci¢city in the
tTG-catalyzed reaction remains unclear, it seems that both the
sequence around the potential target glutamine and the con-
formation of adjacent regions of the protein could determine
whether a glutamine residue can be reactive. To further our
understanding on the role that the relationship sequence-con-
formation plays in the requirements that would de¢ne a glu-
tamine residue as tTG substrate, studies are in progress to-
wards the design and synthesis, by multiple peptide synthesis
techniques, of peptide sequences with a pre-determined secon-
dary structure having glutamine residues at speci¢c positions.
Similar approaches have proved to be crucial in elucidating
the structural determinants of a number of biological proc-
esses [33,34].
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